Domperidone is widely used in the management of gastric disorders, particularly gastro esophageal reflux disorder and peptic ulcer. But the short half-life of domperidone leads to poor compliance and adverse reactions; that is why domperidone in sustained release dosage form is needed to achieve better therapeutic effects and to improve patient compliance. For this purpose sustained release tablets of domperidone were manufactured using different polymers, including hydroxylpropylmethylcellulose (HPMC) K100LV, hydroxylpropylcellulose (HPC) K100M and ethocel (EC-22). The prepared tablets were evaluated for their physical parameters, that is, weight variation was determined with the help of electronic balance, hardness by Monsanto tester, thickness by Vernier caliper and friability of the prepared tablets were determined with the help of Erweka friabilator and drug content was determined by UV/Visible spectrophotometer. The in vitro release studies were carried out for all the formulations of the model drug in a buffer solution of pH 6.8 and 0.1 N HCl solution. The results obtained were analyzed by different pharmacokinetic models, such as zero order, first order, Higuchi model, Hixson-Crowell cube root law and Korsmeyer-Peppas model. All the materials used were available in the local market, so we could be able to minimize the per oral cast of the formulation and also improve the patient compliance by reducing the frequency of dosing, reduce relapse and improve therapeutic outcome.
INTRODUCTION
Domperidone is a synthetic benzimidazole compound, structurally related to butyrophenones and is widely used for the management of gastric disorders particularly Gastro esophageal reflux disorder (GERD) and peptic ulcer. Domperidone is not capable to cross the blood brain barrier (BBB), thus reducing central nervous system and extrapyramidal side effects that can be seen with other dopamine antagonists (Smit et al., 2002) . Dopamine plays an important physiologic role in the regulation of gastric emptying by producing gastric relaxation and inhibiting gastric motility (Weihrauch et al., 1979; Friedman et al., 1983) . But, due to the short half-*Corresponding author. E-mail: muhammadasifkhan.263@gmail com.
life of domperidone, it is advised in the dose range of 10 mg, 3 to 4 times a day that leads to poor compliance and adverse reactions. In order to achieve good patient compliance, formulation of domperidone in sustained release dosage forms is needed. Use of sustained release technologies is the need of the day, as the conventional dosage forms are expensive and with low patient compliance.
The oral route is the most frequently used route for drug administration. Oral dosage forms are intended for systemic effects resulting from drug absorption through gastro intestinal tract (Aulton, 1988) . The oral route of drug administration is the most acceptable route, permit a high degree of accuracy and the dose of the active drug is contained in a relatively small volume (The British Pharmaceutical Codex, 1994) .
Sustained release dosage forms are drug products designed to alter the time and rate of release of the bioactive agent (drug substance). In the last several decades, many different types of controlled-release dosage forms have been developed to improve clinical efficacy of drug and patient compliance (Merkus, 1986) . Generally the rate of drug release is controlled and plasma drug level is maintained at constant level in modified release dosage form (Evelyn et al., 2005) . The sustained release dosage form gradually release drug and maintain plasma drug concentration over an extended period of time, thus achieving better patient compliance and effective clinical management. The onset of pharmacological action is often prolonged, and the duration of therapeutic concentration of the drug is maintained throughout the dosing intervals (Tanaka et al., 2006) . Using modified release techniques, the dosage form can be designed to suit the onset, duration and intensity of action of the drug entity to plasma drug concentrations at steady state over a prolonged period. With sustained drug delivery, steady therapeutic efficacy can be achieved with minimum side effects. Ideal oral drug delivery systems are those, which steadily give a measurable and reproducible amount of the drug over a prolonged period (Sastry and Khan, 1998) . The real challenge in the development of a modified drug delivery system is not just to sustain the drug release, but also to prolong the presence of the dosage form in the stomach or the upper small intestine until all the drug is completely released in the desired period of time (Shailesh et al., 2008) .
Use of sustained release technologies is the need of the day, as the conventional dosage forms are expensive and with low patient compliance. The aim of this work was to develop the sustained release tablet dosage form of domperidone which will be safe and effective with better patient compliance.
Another objective of this work is to evaluate drug release data using various kinetic models and to determine the mechanism of drug release.
MATERIALS AND METHODS
Designing and formulation of domperidone tablets were carried out at Bryon Pharmaceuticals Ltd. (Industrial Area Hayatabad) where the tablets manufacturing facilities are available. Table 1 contains the materials that were used for the manufacturing of different formulations of domperidone sustained release tablet dosage form.
Different formulations of selected drug, sustaining agents and excipients (except lubricants and glidents) were mixed for 15 min in a mixer after passing them through a suitable mesh. Then, the glidents and lubricants were added and mixed for 5 min. The bulk was then compressed using a tablet compression machine (Yasmeen et al., 2005) . The physical tests, such as weight variation was determined with the help of electronic balance, hardness by Monsanto tester, thickness by Vernier caliper and friability of the prepared tablets were determined with the help of Erweka friabilator. To determine the uniformity of drug content, assay procedure for the prepared tablets were performed and absorbance of domperidone solution was determined by UV/Visible spectrophotometer. For dissolution studies (in vitro release) the prepared tablets were subjected in dissolution apparatus having buffer medium of pH 6.8 and the results obtained were analysed by different kinetic models.
RESULTS AND DISCUSSION

Weight variation
The weight of the tablet is the quantity of the granulation that contains the labeled amount of the therapeutic ingredients. For weight variation twenty tablets of each formulation were weighed individually with the help of electronic balance and average weight was determined as shown in Table 2 .
Hardness of tablets
The resistance of the tablets to chipping, abrasion or breakage under conditions of storage, transportation and handling before usage depends on its hardness. If the tablet is too hard, it may not disintegrate in the required period of time or meet the dissolution specification, if it is so soft it will not withstand the handling during subsequent processing, such as coating or packaging and shipping operations. Table 2 shows the average hardness of the tablets of each formulation.
Thickness of tablets
The thicknesses of the tablets were determined by using Vernier caliper. Twenty tablets from each prepared batch of domperidone were taken and average thickness values were calculated. The average thicknesses of all the nine formulations are given in Table 2 .
Friability of tablets
The friability of the tablets was determined for twenty tablets taken randomly from each batch. After weighing, the tablets were placed in the plastic chamber of the friability tester (Erweka tablets friability tester). The friability is evaluated by the following formula:
where W1 is the weight of tablets before testing and W2 is the weight of tablets after testing. The friability of all the nine formulations is expressed as percentage in Table 2 .
Pharmaceutical assay
The tablets of the drug were tested for their drug contents, twenty tablets were selected randomly and transferred to a suitable tare container and weighed, and then average weight per tablet was calculated, the tablets were powdered with the help of mortar and pestle. Domperidone solution was prepared by dissolving the required amount of powder in a suitable solvent. Absorbances of the resultant solutions were measured at 284 nm by using UV/Visible spectrophotometer (Prasad et al., 2009 ). The percentage yield obtained of each formulation is as shown in Table 2 .
In vitro dissolution studies
Dissolution test study was carried out for all the nine batches of domperidone in 0.1 N HCl solution and buffer medium (pH 6.8). For this purpose 900 ml buffer medium (pH 6.8) and 0.1 N HCl solution was placed in each vessel of the United States Pharmacopeia (USP) dissolution apparatus Ι and the medium was allowed to reach the temperature of 37°C. Then 20 mg domperidone tablets were placed in each vessel of the apparatus and operated for first 2 h at the rate of 100 rpm. At the end of the time period, an aliquot (about 5 ml) fluid withdraws, filtered and diluted to 50 ml with dissolution medium. Then 5 ml of dissolution medium was added to each vessel in order to maintain the volume and the apparatus was operated for next time period, the procedure was continued until the time period was completed. Absorbances of the standard and sample solution were measured at the wave length of 285 nm, at the end of every time period (Nagarsenker et al., 1999) . Tablets from the formulations F1, F2, F3, F4, F5, F6, F7, F8 and F9 released the drug 24. 51, 29.32, 20.02, 22.11, 29.32, 12.32, 15.32, 18.56 and 16 .32% at the end of 2 h and sustained the release of the drug for 20 h for formulation F9 at 0.1 N HCl solution. Tablets from the formulations F1, F2, F3, F4, F5, F6, F7, F8 and F9 released the drug 7.526, 11.425, 16.314, 11.358, 9.407, 13.889, 21.125, 18.078 and 16.314% at the end of 2 h and 90.325% of the drug is released by formulation 9 (F9) and the release was sustained for 24 h in buffer solution of pH 6.8. The drug release rate is controlled by the hydration of polymer used, which form gelatinous barrier layer at the surface of the matrix.
To examine the release rate (in-vitro release data) which includes the zero order rate, Equation 1 describes the systems where the release drug rate is independent of its concentration (Hadjiioannou et al., 1993) . 
where M t is the cumulative absolute amount of drug t released at time t, A is the surface area of the controlled release device exposed to the release medium, D is the drug diffusivity in the polymer carrier and c o and c s are the initial drug concentration and the solubility of the drug in the polymer, respectively. Clearly, Equation 4 can be expressed as:
Where M ∞ is the absolute cumulative amount of drug released at infinite time (which should be equal to the absolute amount of drug incorporated within the system at time t = 0) and K is a constant reflecting the design variables of the system. Thus, the fraction of drug released is proportional to the square root of time.
Alternatively, the drug release rate is proportional to the reciprocal of the square root of time. One of the great benefits of these equations is that they are simply employed (Siepmann and Peppas, 2001) .
The Hixson-Crowell cube root law Equation 5 explains the release of drug from controlled release systems where there is an alteration in the surface area and particle size of the matrix tablets (Hixson and Crowell, 1931) .
where Q t is the quantity of drug released in time t, Q 0 is the initial amount of the drug in tablet and K HC is the rate constant for Hixson-Crowell rate equation.
The following plots were made: cumulative (%) drug release versus time (zero order kinetic model); log cumulative of % drug remaining versus time (first order kinetic model); cumulative (%) drug release versus square root of time (Higuchi model) log cumulative (%) drug release versus log time (Korsmeyer model) and cube root of drug (%) remaining in matrix versus time (Hixson-Crowell cube root law).
Mechanism of drug release
Korsmeyer et al (1983) derived a simple relationship that described drug release from a polymeric system.
Drug release kinetics
As shown in Figure 1 , according to kinetic models, was the linear relationship. The best linearity R2 in 0.1 N HCl solution as given in Table 4 is 0.985 while in case of buffer solution pH 6.8 the best linearity was found in Zero order equation plot (Figure 1 ) the R2 value obtained is 0.989 as shown in Table 5 , indicating the release of drug from matrix tablet is independent of the concentration of the drug i-e Super case-II transport as given in Table 3 . 
Conclusion
The sustained release matrix tablets of domperidone were successfully developed. All the polymers showed drug release behavior. Among the polymers used hydroxylpropylmethylcellulose (HPMC) K100LV exhibited maximum drug release. Formulation F9 was selected as optimized one based upon its zero order release kinetics, hydroxylpropylmethylcellulose (HPMC) K100LV at a concentration of 70% released the drug up to 24h in buffer solution of pH 6.8. This may improve the patient compliance by reducing the frequency of dosing and side effects which will ultimately improve the therapeutic outcome.
